Recent Updates
Recently added Catalysts
INCY Positive Sentiment

Samenvatting: De gegevens van Incyte op het congres van de Europese Academie voor Dermatologie en Venereologie (EADV) bevestigen de breedte van Incyte's portfolio op het gebied van ontsteking en auto-immuniteit

Tuesday, September 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Incyte announced that it will present data from its inflammation and autoimmunity portfolio at the European Academy of Dermatology and Venereology (EADV) congress in 2026. The event will take place in Vienna, Austria, from September 30 to October 3, 2026. This presentation underscores the strength and breadth of Incyte's research in these therapeutic areas.

Market Sentiment Analysis

POSITIVE FACTORS

  • Incyte's portfolio shows a strong breadth in inflammation and autoimmunity.
  • Data presentation at EADV 2026 highlights significant research efforts.
  • The event is a prestigious platform for showcasing advancements.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+31%
120-day peak, hindsight
Typical move
2.4%
average across 15 past catalysts
Lead asset
Ruxolitinib
Phase 2 · T-cell Lymphoma

Full Press Release Details

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) heeft vandaag bekendgemaakt dat gegevens uit zijn gehele portfolio op het gebied van ontsteking en auto-immuniteit (IAI) zullen worden gepresenteerd tijdens het congres van de European Academy of Dermatology and Venereology (EADV) 2026, dat van 30 september tot en met 3 oktober 2026 plaatsvindt in Wenen, Oostenrijk. "De breedte van het onderzoek dat op EADV 2026 wordt gepresenteerd, benadrukt de kracht van onze portfolio op het gebied van

Frequently Asked Questions

When will Incyte present at EADV 2026?

Incyte will present at EADV 2026 from September 30 to October 3, 2026.

What is the focus of Incyte's presentation?

The focus will be on data related to inflammation and autoimmunity.

Where is the EADV 2026 congress taking place?

The EADV 2026 congress will be held in Vienna, Austria.

What does Incyte's portfolio emphasize?

Incyte's portfolio emphasizes the breadth of research in inflammation and autoimmunity.

ShareAdd on Google
Tags: INCY Viatris Investor Conferences Healthcare Incyte EADV 2026 inflammation autoimmunity dermatology
Last updated: Sep 22, 2026

Biotech snapshot

Cash runway
$4536M liquidity · $0M/mo burn
Low dilution risk
Lead asset
RuxolitinibPhase 2
T-cell Lymphoma →

Catalyst track record

+31%
best trade around INCY's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for INCY.

See every catalyst's timing & PoA →